• 2014 GIST Summit

    The 2014 GIST Summit was held Saturday September 13, 2014 at MD Anderson Cancer Center in Houston, and it was the best ever! Watch videos now.

    Continue reading
  • UCLA GCAF forum March 24

    GIST Cancer Awareness Foundation and UCLA are hosting a free educational forum for GIST patients and caregivers on March 24 in Los Angeles.  See details below on how to register. For more about GCAF see their website www.gistawareness.org    

    Continue reading
  • Survey on Mutation Analysis

    Boston University School of Medicine is conducting a study regarding GIST patients’ understanding of tumor testing and personalized medicine. Feel free to read more below! The direct link to the survey is: https://bostonu.qualtrics.com/SE/?SID=SV_0MMOLgR37hBH1t3 For any questions or comments, please contact the researchers directly.

    Continue reading
  • 2014 NIH Wildtype GIST Clinic

    For more information about the NIH clinic for pediatric & wildtype GIST, see our webpages about past clinics.  Patients of all ages with wildtype GIST are encouraged to participate.  Participation enables the patient to receive special tests and consultations with wildtype GIST experts from numerous hospitals as well as the NIH staff physicians and researchers. 

    Continue reading
  • Combination trial imatinib + MEK162

    New combination trial for GIST:  imatinib plus MEK inhibitor MEK162 A new clinical trial opened in November 2013 at Memorial Sloan-Kettering Cancer Center to test the combination of imatinib (Gleevec) plus MEK162, an inhibitor of the MEK pathway.  Trial NCT01991379, A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated […]

    Continue reading
  • GIST News from 2012 ASCO

    Becky Bensanhaver and Nancy Berezin attended the ASCO meeting in June 2012 on behalf of GIST Support International and all GIST patients.  This is an effort reqiuring stamina, comfortable shoes, and keen attention to cover the huge meeting and absorb the new information.  MANY THANKS to Nancy and Becky for their hard work!   LINK HERE to […]

    Continue reading
  • Regorafenib Approved

    FDA Approves Stivarga (regorafenib) for GIST On February 25, 2013 the FDA approved regorafenib (brand name Stivarga) for treatment of GIST patients with “advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease” (Gleevec and Sutent). This makes regorafenib the first drug approved for third-line treatment of […]

    Continue reading
  • Votrient approved for sarcoma

    On April 26, 2012  the FDA announced approval of pazopanib (votrient) for soft tissue sarcoma. Earlier the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted March 20, 2012  to approve a New Drug Application for pazopanib tablets (Votrient, GlaxoSmithKline) in the treatment of patients with advanced soft tissue sarcoma who have received previous chemotherapy.  […]

    Continue reading
  • FDA approves adjuvant Gleevec extension to 3 years

    FDA news release, Jan 31, 2012: FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer Confirmatory trials show significantly prolonged survival in patients; drug granted regular approval The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors […]

    Continue reading
  • 2011 GIST Summit: Terrific!

    by Tony Doré   Diverse group, evolving summit The GIST Summits have come a long way since the idea germinated at an informal gathering in a Houston apartment block, back in 2008.  The 2011 summit, held at MD Anderson Cancer Center, attracted a large and diverse group of people from 4 countries and 16 US states.  […]

    Continue reading